Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: Clinical and quality of life consequences

European Journal of Endocrinology

Volumn 156, Issue 1, 2007, Pages 13-19

  Duntas, Leonidas H ^b   Biondi, Bernadette ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COUMARIN DERIVATIVE; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; IODINE 131; LEVOTHYROXINE; OSTEOPROTEGERIN; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RECOMBINANT PROTEIN; THYROXINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DRUG COST; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INTERMETHOD COMPARISON; METASTASIS; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RADIOISOTOPE THERAPY; REVIEW; THYROID CANCER; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDECTOMY; BLOOD PRESSURE; BRAIN CIRCULATION; DRUG EFFECT; HEART RATE; LIPID METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; THYROID TUMOR;

BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; HEART RATE; HUMANS; HYPOTHYROIDISM; LIPID METABOLISM; QUALITY OF LIFE; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROXINE;

EID: 33847720753     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02310     Document Type: Review

References (58)

1. Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006 295 2179-2182.
2. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV & Dorfman SG. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid carcinoma. American Thyroid Association. Archives of Internal Medicine 1996 156 2165-2172.
3. Sclumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A & Wiersinga WM. Follow up of low risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology 2004 150 105-112.
4. Ringel MD & Ladenson PW. Controversies in the follow up and management of well differentiated thyroid carcinoma. Endocrine Related Cancer 2004 11 97-116.
5. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J & Wiersinga W. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology 2005 153 651-659.
6. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW & Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 1433-1441.
7. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garger JR, Wondisford EE, Davies TF, De Groot LJ, Daniels GH, Ross DS & Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888-896.
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD & Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877-3885.
9. Kohlfuerst S, Igerc I & Lind P. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005 15 371-376.
10. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M & Reiner C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 2005 91 926-932.
11. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
12. The American Thyroid Association Guidelines Taskforce. Management guidelines for patient with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109-141.
13. Dow KH, Ferrell BR & Anello C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613-619.
14. Biondi B & Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004 24 1-13.
15. Duntas LH. Thyroid disease and lipids. Thyroid 2002 12 287-293.
16. Cappola AR & Ladenson PW. Hypothyroidisin and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2003 88 2438-2444.
17. Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501-509.
18. Biondi B & Klein I. Cardiovascular abnormalities in subclinical and overt hypothyroidism. In The Thyroid and Cardiovascular Risk, pp 30-35. Eds KM Derwahl, LH Duntas & S Butz, Thieme Verlag: Stuttgart, 2005.
19. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of subclinical thyroid dysfunction on the heart. Annals of Internal Medicine 2002 137 904-914.
20. Fazio S, Biondi B, Lupoli G, Cittadini A, Santomauro M, Tommaselli AP, Lombardi G & Saccà L. Evaluation by noninvasive methods of the effects of acute loss of thyroid hormone on the heart. Angiology 1992 43 287-293.
21. Botella-Carretero JL, Goḿez-Bueno M, Barrios V, Caballero C, García-Robles R, Sancho J & Escobar-Morreale HF. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine Related Cancer 2004 11 345-356.
22. Di Paola R, Alagona C, Pezzino V, Mangiameli S & Regalbuto C. Left ventricular function in acute hypothyroidism: a Doppler echo-cardiography study. Italian Heart Journal 2004 5 857-863.
23. Wieshammer S, Keck FS, Waitzinger J, Kohler J, Adam W, Stauch M & Pfeiffer EF. Left ventricular function at rest and during exercise in acute hypothyroidism. British Heart Journal 1988 60 204-211.
24. Grossman G, Wieshammer S, Keck FS, Goeller V, Glesler M & Hombach V. Doppler echocardiographic evaluation of left ventricular diastolic function in acute hypothyroidism. Clinical Endocrinology 1994 40 227-233.
25. Kahaly G, Mohr-Kahaly S, Beyer J & Meyer J. Left ventricular function analyzed by Doppler and echocardiographic methods in short-term hypothyroidism. American Journal of Cardiology 1995 75 645-648.
26. Wieshammer S, Keck FS, Waitzinger J, Henze E, Loos U, Hombach V & Pfeiffer EF. Acute hypothyroidism slows the rate of left ventricular diastolic relaxation. Canadian Journal of Physiology and Pharmacology 1989 67 1007-1010.
27. Fommei E & Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 1996-2000.
28. Johnson AB, Webber J, Mansell P, Gallen I, Allison SP & Macdonald I. Cardiovascular and metabolic responses to adrenaline infusion in patients with short-term hypothyroidism. Clinical Endocrinology 1995 43 747-751.
29. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S & Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology 2005 152 1-9.
30. Bengel FM, Nekolla SG, Ibrahim R, Weniger C, Ziegler SI & Schwaiger M. Effect of thyroid hormones on cardiac function, geometry and oxidative metabolism assessed noninvasively by positron emission tomograpy and magnetic resonance imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 1822-1827.
31. Bucerius J, Joe AY, Palmedo H, Reinhardt MJ & Biersack HJ. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid 2006 16 369-374.
32. Staub JJ, Althaus BU, Engler H, Ryff AS, Trabucco P, Marquardt K, Burckhardt D, Girard J & Weintraub BD. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve and metabolic impact on peripheral target tissues. American Journal of Medicine 1992 92 631-642.
33. Duntas LH, Mantzou E & Koutras DA. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002 12 1003-1007.
34. Dedecjus M, Masson D, Gautier T, de Barros JP, Gambert P, Lewinski A, Adamczewski Z, Moulin P & Lagrost L. Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short term hypothyroidism lack of relationship to lipoprotein abnormalities. Clinical Endocrinology 2003 58 581-588.
35. Lien EA, Nedrebo BG, Varbaug JE, Nygard O, Aakvaag A & Ucland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 1049-1053.
36. Bicikova M, Hampl R, Hill M, Stanicka S, Tallova J & Vondra K. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidisin and their changes following thyroid hormone supplementation. Clinical Chemistry and Laboratory Medicine 2003 41 284-292.
37. Thomsen AF, Kvist TK, Andersen PK & Kessing LV. Increased risk of developing affective disorder in patients with hypothyroidism: a register-based study. Thyroid 2005 15 700-707.
38. Nagamachi S, Jinnouchi S, Nishii R, Ishida Y, Fujita S, Futami S, Kodama T, Tamura S & Kawai K. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy - analysis by tc-99m-HMPAO and SPM96. Annals of Nuclear Medicine 2004 18 469-477.
39. Constant EL, De Volder AG, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J & Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. Journal of Clinical Endocrinology and Metabolism 2001 86 3864-3870.
40. WHOQOL Group. Study protocol for the World Health Organisation project to develop a quality of life assessment instrument (the WHOQOL). Quality of Life Research 1993 2 153-159.
41. Kaplan M. Progress in thyroid cancer. Endocrinology and Metabolism Clinics of North America 1990 19 469-478.
42. Giusti M, Sibilla F, Cappi C, Dellepiane M, Tombesi F, Ceresola E, Augeri C, Rasore E & Minuto F. A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. Journal of Endocrinological Investigation 2005 28 599-608.
43. Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147-1155.
44. Nijhuis TF, van Weperen W & de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999 21 98-100.
45. Botella-Carretero JI, Galán JM, Caballero C, Sancho I & Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine Related Cancer 2 2003 10 601-610.
46. Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, Bockisch A, Sent W & Görges R. Health-related quality of life, anxiety and depression in thyroid cancer patient under short-term hypothyroidism and TSH suppressive levothyroxine treatment. European Journal of Endocrinology 2005 6 755-763.
47. Cohen O, Dabhi S, Karasik A & Zwas SZ. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. European Journal of Endocrinology 2004 150 285-290.
48. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC & Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 2006 91 878-884.
49. US Preventive Services Task Force Ratings Strength of Recommendations and Quality of Evidence 2000-2003. Guide to Clinical Preventive Services, edn 3, Periodic Updates. Agency for Healthcare Research and Quality. Rockville, MD.
50. Wolf M, Weigert A & Kreymann G. Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy. European Journal of Endocrinology 1996 134 168-173.
51. Botella-Carretero JI, Prados A, Manzano L, Montero MT, Escribano L, Sancho J & Escobar-Morreate HF. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. European Journal of Endocrinology 2005 153 223-230
52. Kao PF, Lin JD, Chiu CT, Hsu HT, See LC & Tzen KY. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Journal of Gastroenterology and Hepatology 2004 19 655-660.
53. Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G & Fazio S. Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2003 88 211-214.
54. Murialdo G, Casu M, Cappi C, Patrone V, Repetto E, Copello F, Minuto F & Giusti M. Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on 1-thyroxine-suppressive therapy for differentiated thyroid carcinoma. Hormone Research 2005 64 100-106.
55. Giusti M, Valenti S, Guazzini B, Molinari E, Cavallero D, Augeri C & Minuto F. Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant. Journal of Endocrinological Investigation 2003 26 1192-1197.
56. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G & Carella C. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. Journal of Bone and Mineral Research 2005 20 480-486.
57. Luster M, Sherman SL, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H & Reiners C. Comparison of radionuclide bioldnetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1371-1377.
58. de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ & de Klerk JM. Bone marrow dosimetry and safety of high 1311 activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. Journal of Nuclear Medicine 2004 45 1549-1554.